GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Altman Z-Score

Sight Sciences (Sight Sciences) Altman Z-Score : 1.35 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.35 is in distress zone. This implies bankruptcy possibility in the next two years.

Sight Sciences has a Altman Z-Score of 1.35, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Sight Sciences's Altman Z-Score or its related term are showing as below:

SGHT' s Altman Z-Score Range Over the Past 10 Years
Min: 0.23   Med: 3.44   Max: 14.33
Current: 1.35

During the past 6 years, Sight Sciences's highest Altman Z-Score was 14.33. The lowest was 0.23. And the median was 3.44.


Sight Sciences Altman Z-Score Historical Data

The historical data trend for Sight Sciences's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Altman Z-Score Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial - - 10.27 5.25 1.38

Sight Sciences Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 3.22 0.23 1.38 1.15

Competitive Comparison of Sight Sciences's Altman Z-Score

For the Medical Devices subindustry, Sight Sciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Altman Z-Score falls into.



Sight Sciences Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Sight Sciences's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.9025+1.4*-1.9996+3.3*-0.3169+0.6*5.9792+1.0*0.5239
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $155.56 Mil.
Total Current Assets was $152.09 Mil.
Total Current Liabilities was $11.69 Mil.
Retained Earnings was $-311.06 Mil.
Pre-Tax Income was -16.249 + -10.681 + -12.957 + -14.746 = $-54.63 Mil.
Interest Expense was -1.204 + -1.351 + -1.432 + -1.349 = $-5.34 Mil.
Revenue was 19.265 + 18.751 + 20.009 + 23.471 = $81.50 Mil.
Market Cap (Today) was $277.14 Mil.
Total Liabilities was $46.35 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(152.089 - 11.693)/155.56
=0.9025

X2=Retained Earnings/Total Assets
=-311.056/155.56
=-1.9996

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-54.633 - -5.336)/155.56
=-0.3169

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=277.142/46.351
=5.9792

X5=Revenue/Total Assets
=81.496/155.56
=0.5239

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Sight Sciences has a Altman Z-Score of 1.35 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Sight Sciences  (NAS:SGHT) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Sight Sciences Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sight Sciences (Sight Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Executives
Jeremy B. Hayden officer: Chief Legal Officer 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park officer: Chief Operating Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi director, 10 percent owner, officer: President and CEO C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi director, officer: Chief Technology Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz director C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link officer: Chief Commercial Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein officer: See remarks 326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg officer: See Remarks C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker director C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick officer: Chief Financial Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089

Sight Sciences (Sight Sciences) Headlines

From GuruFocus

Sight Sciences Announces 1,000th TearCare� Customer Installation

By Stock market mentor Stock market mentor 01-26-2023

Sight Sciences Announces Addition of New Director Catherine Mazzacco

By sperokesalga sperokesalga 06-09-2023